Compounded peptide education
No FDA-approved counterpartDSIP / Emideltide
No FDA-approved counterpart was identified. FDA states that it lacks sufficient safety information for compounded emideltide.
A transparent starting point
What to know before considering DSIP / Emideltide
This page is educational and does not diagnose a condition or recommend a medication. ASR uses a clinical evaluation to determine whether a compounded peptide is appropriate for an individual patient and whether it is currently available.
FDA and compounding status
No FDA-approved counterpart was identified. FDA states that it lacks sufficient safety information for compounded emideltide.
Compounded drugs can be appropriate for an identified patient when a licensed prescriber determines that the patient's needs are not met by an FDA-approved product. They do not undergo FDA premarket review for safety, effectiveness, or manufacturing quality.
Evidence and limitations
Research quality, studied populations, dosing, formulation, and route can differ from the compounded preparation discussed in a wellness setting. Results cannot be guaranteed, and findings about one product or route should not be applied automatically to another.
Risks and monitoring
Potential side effects, contraindications, interactions, pregnancy and breastfeeding considerations, storage, dosing, and follow-up depend on the exact formulation and the patient's health history. These topics must be reviewed with the prescribing clinician before treatment.